713 related articles for article (PubMed ID: 32650852)
21. Human Papillomaviruses, p16INK4a and Akt expression in basal cell carcinoma.
Paolini F; Carbone A; Benevolo M; Silipo V; Rollo F; Covello R; Piemonte P; Frascione P; Capizzi R; Catricalà C; Venuti A
J Exp Clin Cancer Res; 2011 Nov; 30(1):108. PubMed ID: 22082146
[TBL] [Abstract][Full Text] [Related]
22. Comparison of PTCH1, COX-2, p53, and Ki-67 protein expression in basal cell carcinomas of nodular and superficial subtypes arising on the head and trunk.
Khalesi M; Waterhouse M; Whiteman DC; Johns R; Rosendahl C; Hackett T; Pollak T; Kimlin MG; Hacker E; Neale RE;
Int J Dermatol; 2016 Oct; 55(10):1096-105. PubMed ID: 27126210
[TBL] [Abstract][Full Text] [Related]
23. Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults.
Ferrante di Ruffano L; Dinnes J; Chuchu N; Bayliss SE; Takwoingi Y; Davenport C; Matin RN; O'Sullivan C; Roskell D; Deeks JJ; Williams HC;
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD013187. PubMed ID: 30521689
[TBL] [Abstract][Full Text] [Related]
24. Increased immunoreactivity of membrane type-1 matrix metalloproteinase (MT1-MMP) and β-catenin in high-risk basal cell carcinoma.
Oh ST; Kim HS; Yoo NJ; Lee WS; Cho BK; Reichrath J
Br J Dermatol; 2011 Dec; 165(6):1197-204. PubMed ID: 21729023
[TBL] [Abstract][Full Text] [Related]
25. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical galectin-3 expression in non-melanoma skin cancers.
Kapucuoglu N; Basak PY; Bircan S; Sert S; Akkaya VB
Pathol Res Pract; 2009; 205(2):97-103. PubMed ID: 18951731
[TBL] [Abstract][Full Text] [Related]
27. Basal Cell Carcinoma Multiplicity - a Retrospective Analysis of 899 Biopsy-proven Patients from a Single Institute.
Bartos V; Kullová M
Klin Onkol; 2017; 30(3):197-201. PubMed ID: 28612616
[TBL] [Abstract][Full Text] [Related]
28. p16 gene expression in basal cell carcinoma.
Eshkoor SA; Ismail P; Rahman SA; Oshkour SA
Arch Med Res; 2008 Oct; 39(7):668-73. PubMed ID: 18760195
[TBL] [Abstract][Full Text] [Related]
29. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma.
Ansarin H; Daliri M; Soltani-Arabshahi R
Eur J Dermatol; 2006; 16(5):543-7. PubMed ID: 17101476
[TBL] [Abstract][Full Text] [Related]
30. Immunoexpression of p53 and COX-2 in basal cell carcinoma.
Enache AO; Stepan AE; Mărgăritescu C; Pătraşcu V; Ciurea RN; Simionescu CE; Camen A
Rom J Morphol Embryol; 2018; 59(4):1115-1120. PubMed ID: 30845292
[TBL] [Abstract][Full Text] [Related]
31. Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis.
Kaur P; Mulvaney M; Carlson JA
Am J Dermatopathol; 2006 Aug; 28(4):293-307. PubMed ID: 16871032
[TBL] [Abstract][Full Text] [Related]
32. Basosquamous cell carcinoma: a survey of 76 patients and a comparative analysis of basal cell carcinomas and squamous cell carcinomas.
Betti R; Crosti C; Ghiozzi S; Cerri A; Moneghini L; Menni S
Eur J Dermatol; 2013; 23(1):83-6. PubMed ID: 23238332
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and P53.
Abdelsayed RA; Guijarro-Rojas M; Ibrahim NA; Sangueza OP
J Cutan Pathol; 2000 Apr; 27(4):169-75. PubMed ID: 10774937
[TBL] [Abstract][Full Text] [Related]
34. Immunolabeling pattern of podoplanin (d2-40) may distinguish basal cell carcinomas from trichoepitheliomas: a clinicopathologic and immunohistochemical study of 49 cases.
Plaza JA; Ortega PF; Bengana C; Stockman DL; Suster S
Am J Dermatopathol; 2010 Oct; 32(7):683-7. PubMed ID: 20559122
[TBL] [Abstract][Full Text] [Related]
35. Anatomic location of Basal cell carcinomas may favor certain histologic subtypes.
Betti R; Radaelli G; Bombonato C; Crosti C; Cerri A; Menni S
J Cutan Med Surg; 2010; 14(6):298-302. PubMed ID: 21084023
[TBL] [Abstract][Full Text] [Related]
36. Expression of CXCR4, MMP-13 and β-catenin in different histological subtypes of facial basal cell carcinoma.
Ciurea ME; Cernea D; Georgescu CC; Cotoi OS; Pătraşcu V; Pârvănescu H; Popa D; Pârvănescu V; Ciurea RN; Mercuţ R
Rom J Morphol Embryol; 2013; 54(4):939-51. PubMed ID: 24398989
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of alpha1 (IV) and alpha5 (IV) collagen chains in basal-cell carcinoma.
Quatresooz P; Martalo O; Piérard GE
J Cutan Pathol; 2003 Oct; 30(9):548-52. PubMed ID: 14507402
[TBL] [Abstract][Full Text] [Related]
38. Actin expression in purely nodular versus nodular-infiltrative basal cell carcinoma.
Law AM; Oliveri CV; Pacheco-Quinto X; Horenstein MG
J Cutan Pathol; 2003 Apr; 30(4):232-6. PubMed ID: 12680952
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic accuracy of punch biopsy in subtyping basal cell carcinoma.
Kamyab-Hesari K; Seirafi H; Naraghi ZS; Shahshahani MM; Rahbar Z; Damavandi MR; Naraghi MM; Rezvani M; Aghazadeh N
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):250-3. PubMed ID: 22989368
[TBL] [Abstract][Full Text] [Related]
40. Infiltrative basal cell carcinoma occurring in sites of biopsy-proven nodular basal cell carcinoma.
Swetter SM; Yaghmai D; Egbert BM
J Cutan Pathol; 1998 Sep; 25(8):420-5. PubMed ID: 9826167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
